Literature DB >> 28935570

Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis.

Amy Anzovino1, Shannon Chiang1, Bronwyn E Brown2, Clare L Hawkins3, Des R Richardson4, Michael L-H Huang5.   

Abstract

Nuclear factor-erythroid 2-related factor-2 (Nrf2) is a master regulator of the antioxidant response. However, studies in models of Friedreich ataxia, a neurodegenerative and cardiodegenerative disease associated with oxidative stress, reported decreased Nrf2 expression attributable to unknown mechanisms. Using a mouse conditional frataxin knockout (KO) model in the heart and skeletal muscle, we examined the Nrf2 pathway in these tissues. Frataxin KO results in fatal cardiomyopathy, whereas skeletal muscle was asymptomatic. In the KO heart, protein oxidation and a decreased glutathione/oxidized glutathione ratio were observed, but the opposite was found in skeletal muscle. Decreased total and nuclear Nrf2 and increased levels of its inhibitor, Kelch-like ECH-associated protein 1, were evident in the KO heart, but not in skeletal muscle. Moreover, a mechanism involving activation of the nuclear Nrf2 export/degradation machinery via glycogen synthase kinase-3β (Gsk3β) signaling was demonstrated in the KO heart. This process involved the following: i) increased Gsk3β activation, ii) β-transducin repeat containing E3 ubiquitin protein ligase nuclear accumulation, and iii) Fyn phosphorylation. A corresponding decrease in Nrf2-DNA-binding activity and a general decrease in Nrf2-target mRNA were observed in KO hearts. Paradoxically, protein levels of some Nrf2 antioxidant targets were significantly increased in KO mice. Collectively, cardiac frataxin deficiency reduces Nrf2 levels via two potential mechanisms: increased levels of cytosolic Kelch-like ECH-associated protein 1 and activation of Gsk3β signaling, which decreases nuclear Nrf2. These findings are in contrast to the frataxin-deficient skeletal muscle, where Nrf2 was not decreased.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28935570     DOI: 10.1016/j.ajpath.2017.08.021

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

1.  Hypoxia Rescues Frataxin Loss by Restoring Iron Sulfur Cluster Biogenesis.

Authors:  Tslil Ast; Joshua D Meisel; Shachin Patra; Hong Wang; Robert M H Grange; Sharon H Kim; Sarah E Calvo; Lauren L Orefice; Fumiaki Nagashima; Fumito Ichinose; Warren M Zapol; Gary Ruvkun; David P Barondeau; Vamsi K Mootha
Journal:  Cell       Date:  2019-04-25       Impact factor: 41.582

Review 2.  Friedreich ataxia: clinical features and new developments.

Authors:  Medina Keita; Kellie McIntyre; Layne N Rodden; Kim Schadt; David R Lynch
Journal:  Neurodegener Dis Manag       Date:  2022-06-29

3.  Effect of di(2-ethylhexyl) phthalate on Nrf2-regulated glutathione homeostasis in mouse kidney.

Authors:  Ines Amara; Amal Salah; Rim Timoumi; Emna Annabi; Maria Scuto; Angela Trovato; Fadwa Neffati; Vittorio Calabrese; Salwa Abid-Essefi
Journal:  Cell Stress Chaperones       Date:  2020-06-04       Impact factor: 3.827

Review 4.  Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease.

Authors:  Elisia Clark; Joseph Johnson; Yi Na Dong; Elizabeth Mercado-Ayon; Nathan Warren; Mattieu Zhai; Emily McMillan; Amy Salovin; Hong Lin; David R Lynch
Journal:  Neuronal Signal       Date:  2018-11-02

5.  Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.

Authors:  Scott A Reisman; Sarabjit S Gahir; Chun-Yue I Lee; Joel W Proksch; Mitsumasa Sakamoto; Keith W Ward
Journal:  Drug Des Devel Ther       Date:  2019-04-17       Impact factor: 4.162

6.  Nrf2 Induction Re-establishes a Proper Neuronal Differentiation Program in Friedreich's Ataxia Neural Stem Cells.

Authors:  Piergiorgio La Rosa; Marta Russo; Jessica D'Amico; Sara Petrillo; Katia Aquilano; Daniele Lettieri-Barbato; Riccardo Turchi; Enrico S Bertini; Fiorella Piemonte
Journal:  Front Cell Neurosci       Date:  2019-07-31       Impact factor: 5.505

7.  Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs.

Authors:  Sara Petrillo; Jessica D'Amico; Piergiorgio La Rosa; Enrico Silvio Bertini; Fiorella Piemonte
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

Review 8.  Emerging Regulatory Role of Nrf2 in Iron, Heme, and Hemoglobin Metabolism in Physiology and Disease.

Authors:  Shuya Kasai; Junsei Mimura; Taku Ozaki; Ken Itoh
Journal:  Front Vet Sci       Date:  2018-10-10

Review 9.  Unraveling the Role of Heme in Neurodegeneration.

Authors:  Deborah Chiabrando; Veronica Fiorito; Sara Petrillo; Emanuela Tolosano
Journal:  Front Neurosci       Date:  2018-10-09       Impact factor: 4.677

Review 10.  The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis.

Authors:  Michael L-H Huang; Shannon Chiang; Danuta S Kalinowski; Dong-Hun Bae; Sumit Sahni; Des R Richardson
Journal:  Oxid Med Cell Longev       Date:  2019-04-07       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.